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UK legislation on analgesic packs: before and after study of long
term effect on poisonings
Keith Hawton, Sue Simkin, Jonathan Deeks, Jayne Cooper, Amy Johnston, Keith Waters, Morag Arundel, William
Bernal, Bridget Gunson, Mark Hudson, Deepak Suri, Kenneth Simpson
Abstract
Objective To evaluate the long term effect of legislation
limiting the size of packs of analgesics sold over the counter.
Design Before and after study.
Setting Suicides in England and Wales, data from six liver units
in England and Scotland and five general hospitals in England,
and UK data on sales of analgesics, between September 1993
and September 2002.
Data sources Office for National Statistics; six liver units in
England and Scotland; monitoring systems in general hospitals
in Oxford, Manchester, and Derby; and Intercontinental
Medical Statistics Health UK.
Main outcome measures Deaths by suicidal overdose with
paracetamol, salicylates, or ibuprofen; numbers of patients
admitted to liver units, listed for liver transplant, and
undergoing transplantations for paracetamol induced
hepatotoxicity; non-fatal self poisonings with analgesics and
numbers of tablets taken; and sales figures for analgesics.
Results Suicidal deaths from paracetamol and salicylates were
reduced by 22% (95% confidence interval 11% to 32%) in the
year after the change in legislation on 16 September 1998, and
this reduction persisted in the next two years. Liver unit
admissions and liver transplants for paracetamol induced
hepatotoxicity were reduced by around 30% in the four years
after the legislation. Numbers of paracetamol and salicylate
tablets in non-fatal overdoses were reduced in the three years
after the legislation. Large overdoses were reduced by 20% (9%
to 29%) for paracetamol and by 39% (14% to 57%) for
salicylates in the second and third years after the legislation.
Ibuprofen overdoses increased after the legislation, but with
little or no effect on deaths.
Conclusion Legislation restricting pack sizes of analgesics in
the United Kingdom has been beneficial. A further reduction in
pack sizes could prevent more deaths.
Introduction
Legislation to limit the size of packs of analgesics (paracetamol,
salicylates, and their compounds) sold over the counter was
introduced in the United Kingdom on 16 September 1998 to try
to reduce the mortality and morbidity associated with deliberate
overdoses, especially with paracetamol. The increasing problem
of paracetamol overdoses had been highlighted for several years
in the United Kingdom and elsewhere.1–9 The legislation reduced
the previously unrestricted sale limit for pharmacies to a
maximum of 32 tablets and for other retail outlets from 24 to 16
tablets.10 The main aim of the legislation was to reduce
household stocks of analgesics and the associated danger of
overdoses from these supplies.11 12
We previously showed noticeable declines in numbers of
large overdoses, deaths from paracetamol and salicylate
overdose, and paracetamol related liver transplants in the year
after the legislation was introduced.4 Other evidence largely sup-
ported these findings.13–16 We have now assessed the legislation’s
longer term effect and investigated possible substitution of over-
dose method with the non-steroidal anti-inflammatory drug ibu-
profen, which was not included in the legislation.17
Methods
Outcome measures
Mortality from overdoses
Data on drug related deaths (suicides, open verdicts, and
accidental poisonings) in England and Wales, 1993 to 2001, were
supplied by the Office for National Statistics. We extracted data
on deaths of people aged 12 years and over involving paraceta-
mol, salicylates, or ibuprofen either alone or in combination with
other drugs (excluding co-proxamol, which is only available on
prescription).
Liver transplantation and referrals to liver units
From all but one of the liver units in England and Scotland we
obtained data on numbers of patients admitted after
paracetamol overdose, those listed for liver transplant, and those
undergoing transplantation, between 1996 and 2002.
Non-fatal self poisoning
Data on presentations between 1997 and 2001 for self poisoning
with paracetamol, paracetamol compounds (excluding
co-proxamol), salicylates, salicylate compounds, ibuprofen, and
other drugs were collected from five general hospitals (one in
Oxford and two each in Manchester and Derby). We noted the
numbers of tablets taken, and we made standard approximations
for imprecise amounts.
Sales data
Intercontinental Medical Statistics supplied data on sales of anal-
gesics in the United Kingdom.We compared sales to pharmacies
and other outlets after the legislation was introduced with those
in the penultimate year before the change in law (pack sizes were
changing in the year before legislation).
Sales data for paracetamol, salicylates, and ibuprofen are on bmj.com
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Statistical analyses
We used Poisson regression models to analyse event counts.
Models were stratified by hospital and allowed for over-
dispersion. Using inverse variance weighted averages across hos-
pitals, dosages were analysed with geometric means.
The effects of the legislation were summarised as relative
rates and ratios of geometric means, with 95% confidence inter-
vals. From sales data we extracted the numbers of packets and
tablets sold in each year for each product type, and we computed
mean pack sizes.
Data for different outcomes were available for different years.
We grouped these to provide adequate power for analysis. We
also analysed the data on mortality by estimating the underlying
trend across eight years and by testing for a step change when
the legislation was introduced.
Results
Deaths due to paracetamol and salicylate overdoses
Compared with the two years before the legislation, significant
decreases in deaths in the year after the legislation involving
either paracetamol alone ( − 29%, 95% confidence interval
− 13% to − 41%) or salicylates alone ( − 46%, − 8% to − 68%)
were sustained in the subsequent two years (table 1). Findings
were similar for paracetamol or salicylates taken with other
drugs (including in compounds).
Between September 1993 and September 2001 there were
underlying non-significant upward trends in deaths due to para-
cetamol overdose and downward trends in deaths due to
salicylate overdose. Allowing for these trends, we found clear evi-
dence of downward step changes in deaths from overdoses of
both paracetamol and salicylates, either taken alone or with
other drugs, which corresponded to the timing of the legislation
(see table 1).
Analysis of all deaths due to poisoning also showed a down-
ward step change corresponding to the timing of the legislation
(see table 1). The change was much smaller, however, than those
for the drugs covered by the legislation. All findings were similar
when restricted to suicides and open verdicts (data not shown).
On the basis of mortality during 1993-8, 199 deaths were
avoided in the three years after the legislation—118 involving
paracetamol and 81 involving salicylates.
Deaths due to ibuprofen overdose
Few deaths involved ibuprofen: four accidental deaths and seven
open verdict or suicide deaths occurred in the five years before
the legislation and four and nine deaths occurred, respectively, in
the subsequent three years. All these deaths also involved other
drugs. The increased annual incidence of all deaths represented
a 2.2-fold rise (95% confidence interval 0.95 to 4.94) and of open
verdicts and suicides a 2.1-fold rise (0.80 to 5.75).
Admissions to liver units and numbers of liver transplants
We found reductions of around 30% in numbers of people
admitted to liver units because of paracetamol induced
hepatotoxicity, those listed for liver transplant, and actual
transplantations in both the first (1998-2000) and second
(2000-2) periods after the introduction of the legislation (table
2). A different pattern for one unit produced significant hetero-
geneity in number of admissions for paracetamol poisoning
during 2000-2.
Mean annual admissions for paracetamol poisoning
decreased from 349 in the two years before the legislation to 230
in the four years afterwards, listings for liver transplantation
decreased from 43 to 30, and transplants decreased from 32 to
21.5.
Non-fatal self poisonings
Overall, there was a 15% (9% to 21%) reduction in presentations
to hospital for paracetamol overdoses in the year after the legis-
lation, but no reduction in subsequent years. Numbers of
salicylate overdoses did not significantly change, whereas the
numbers of ibuprofen overdoses increased by 27% (11% to 44%)
in the second and third years (table 3).
Numbers of tablets taken in paracetamol and salicylate over-
doses significantly decreased in the three years after the legisla-
tion (table 4). Reductions in the second and third years after the
legislation were significantly larger than in the first year for over-
doses involving paracetamol and salicylates, but not for
overdoses with paracetamol alone. We found no major change
for overdoses with ibuprofen alone, although the mean number
of tablets in overdoses that involved ibuprofen decreased during
the second and third years after the legislation.
Only large (more than 32 tablets) paracetamol overdoses
decreased significantly in the year after the legislation (table 5).
Significant decreases in large overdoses of paracetamol alone
and of any paracetamol and salicylates occurred in the second
and third years after the legislation. Numbers of large ibuprofen
overdoses did not change significantly.
Sales data
Mean pack sizes decreased significantly between 1996-7 and
1998-9 for paracetamol (35 to 24 tablets per packet) and aspirin
Table 1 Deaths related to paracetamol and salicylates among people aged 12 years and over in England and Wales, trends in deaths from poisoning
1993-2001, and change associated with legislation
Variable
Mortality before
legislation*
Mortality after
legislation*
% (95% CI) change
for year after
legislation v 2 years
before P value
% (95% CI)
change for years
2 and 3 after
legislation v 2
years before P value
Annual % trend
(95% CI)† P value
% step change in
1998 (95% CI)† P value1993-6 1996-8 1998-9
1999-2001
Paracetamol
alone
161 192 137 127 −29 (−41 to −13) 0.001 −34 (−44 to −22) <0.001 3.6 (−0.8 to 8.3) 0.11 −35 (−43 to −20) <0.001
Any paracetamol‡ 284 327 265 260 −19 (−30 to −6) 0.004 −20 (−29 to −11) <0.001 2.0 (−1.3 to 5.4) 0.24 −20 (−31 to −6) 0.006
Salicylates alone 34 32 17 10 −46 (−68 to −8) 0.02 −70 (−82 to −50) <0.001 −6.6 (−15.8 to 3.7) 0.2 −52 (−73 to −16) 0.01
Any salicylates‡ 57 46 27 25 −41 (−61 to −9) 0.02 −45 (−61 to −22) 0.001 −7.2 (−14.6 to 0.7) 0.07 −33 (−56 to 2) 0.06
Any paracetmol
or salicylates‡
330 364 284 274 −22 (−32 to −11) <0.001 −25 (−33 to −16) <0.001 0.9 (−2.2 to 4.1) 0.57 −22 (−33 to −10) <0.001
All deaths due to
poisoning
2092 2242 2186 2086 −2 (−7 to 3) 0.33 −7 (−11 to −3) 0.001 1.8 (0.5 to 3.0) 0.005 −8 (−13 to −3) 0.004
*Suicides, open verdicts, and accidental poisonings.
†Analysis across five years before and three years after legislation.
‡Includes multiple drugs and compounds.
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(61 to 25 tablets per packet), although they subsequently
increased slightly (see figure on bmj.com). The sales of paraceta-
mol rose after the legislation, so overall there was little effect on
total numbers of tablets sold (520 million in 1996-7, 580 million
in 2001-2). Sales data for paracetamol compounds followed a
similar pattern. The sales of aspirin remained almost constant
(11 million packs in 1996-7, 12 million packs in 2001-2) whereas
the number of tablets sold was approximately halved.
Discussion
Legislation introduced in the United Kingdom in September
1998 to reduce the size of packs of paracetamol and salicylates
sold over the counter has significantly reduced the size of
overdoses, with consequent reductions in morbidity and mortal-
ity. Although some substitution of self poisoning with ibuprofen
may have occurred, few deaths due to poisoning involved
ibuprofen, and in all cases other drugs were involved. Ibuprofen
is known to be relatively safe in overdose18 and is therefore
unlikely to have been the cause of death. The numbers of tablets
used in ibuprofen overdoses did not change significantly after
the legislation was introduced, suggesting that the legislation’s
effect on overdose size was restricted to the targeted drugs.
An unavoidable limitation of our study is its naturalistic
design; thus other factors might have influenced our findings.
Allowing for underlying trends, however, our analysis showed a
Table 2 Annual numbers and relative incidence rates for admissions for liver transplants, listings, and transplantations due to paracetamol poisoning. Values
are incidence rate ratios (95% confidence intervals) unless stated otherwise
Variable related to
paracetamol poisoning
Period in relation to introduction of legislation
Years 1 and 2 after v
years 1 and 2 before
Pooled
incidence rate
ratio; P value
Years 3 and 4 after v
years 1 and 2 before
Pooled
incidence
rate ratio; P
value
P value for
years 3 and 4
after v years 1
and 2 after
2nd year
before
Year
before
Year
after
2nd
year
after
3rd
year
after
4th
year
after
Admissions:
Birmingham 82 53 40 28 35 47 0.50 (0.38 to 0.67) 0.71
(0.60 to 0.84);
<0.001
0.61 (0.46 to 0.80) 0.61
(0.48 to 0.77);
<0.001
0.25
Edinburgh 59 32 40 32 45 37 0.79 (0.58 to 1.08) 0.90 (0.67 to 1.21)
London (Royal Free) 19 12 10 9 21 20 0.61 (0.35 to 1.08) 1.32 (0.83 to 2.10)
London (King’s
College)
102 127 103 79 49 35 0.79 (0.65 to 0.97) 0.37 (0.29 to 0.47)
Leeds 73 76 60 47 39 38 0.72 (0.56 to 0.92) 0.52 (0.39 to 0.68)
Newcastle 34 29 18 28 28 32 0.73 (0.50 to 1.07) 0.95 (0.67 to 1.35)
Total 369 329 271 223 217 209
Test for between centre
differences
Q=7.55, df=5 0.18 Q=41.7, df=5 <0.001
Listing for liver
transplant:
Birmingham 5 7 1 3 5 5 0.33 (0.11 to 1.03) 0.69
(0.48 to 0.99);
0.04
0.83 (0.36 to 1.93) 0.71
(0.49 to 1.02);
0.06
0.88
Edinburgh 7 2 3 7 3 2 1.11 (0.45 to 2.73) 0.56 (0.19 to 1.66)
London (Royal Free) 2 1 0 0 3 0 0* 1.00 (0.20 to 4.95)
London (King’s
College)
11 20 12 12 10 5 0.77 (0.45 to 1.32) 0.48 (0.26 to 0.90)
Leeds 9 8 9 4 6 4 0.76 (0.37 to 1.57) 0.59 (0.27 to 1.28)
Newcastle 10 4 3 5 8 10 0.57 (0.24 to 1.36) 1.29 (0.64 to 2.59)
Total 44 42 28 31 35 26
Test for between centre
differences
Q=6.43, df=5 0.27 Q=5.09, df=5 0.41
Liver transplants:
Birmingham 4 6 1 2 4 4 0.30 (0.08 to 1.09) 0.64
(0.43 to 0.95);
0.03
0.80 (0.32 to 2.03) 0.70
(0.48 to 1.03);
0.07
0.72
Edinburgh 5 2 1 6 3 2 1.00 (0.35 to 2.85) 0.71 (0.23 to 2.25)
London (Royal Free) 2 1 0 0 3 0 0* 1.00 (0.20 to 4.95)
London (King’s
College)
8 12 9 9 7 3 0.90 (0.48 to 1.70) 0.50 (0.23 to 1.07)
Leeds 6 7 4 3 3 3 0.54 (0.21 to 1.35) 0.46 (0.18 to 1.21)
Newcastle 8 3 2 4 4 9 0.55 (0.20 to 1.47) 1.18 (0.53 to 2.64)
Total 33 31 17 24 24 21
Test for between centre
differences
Q=6.48, df=5 0.26 Q=3.43, df=5 0.63
*Inestimable.
Table 3 Annual numbers of non-fatal self poisonings (Oxford, Manchester, and Derby combined) due to specific drug categories, and percentage change in
number of overdoses. Values are percentage change in numbers (95% confidence intervals) unless stated otherwise
Drug
Annual No of non-fatal self poisonings in relation to
introduction of legislation
Year after legislation v
year before P value
Years 2 and 3 after
legislation v year before P value
P value for difference
between years 2 and 3
after legislation v year
after
Year
before
Year
after
2nd year
after 3rd year after
Paracetamol alone 825 624 757 781 −24 (−32 to −16) <0.001 −7 (−14 to 1) 0.1 <0.001
Any paracetamol 1733 1472 1681 1686 −15 (−21 to −9) <0.001 −3 (−8 to 3) 0.33 <0.001
Salicylates alone 79 64 77 64 −19 (−42 to 13) 0.21 −11 (−32 to 18) 0.42 0.52
Any salicylates 329 307 312 295 −7 (−20 to 9) 0.38 −8 (−19 to 5) 0.24 0.87
Ibuprofen alone 96 113 156 133 18 (−10 to 55) 0.24 51 (19 to 90) 0.001 0.03
Any ibuprofen 316 332 399 402 5 (−10 to 23) 0.53 27 (11 to 44) <0.001 0.004
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substantial downward step change in numbers of deaths from
paracetamol and salicylate poisoning immediately after the
legislation was introduced, with only a small change in overall
deaths due to poisoning. This, together with decreases in the size
of overdoses and statistics from liver units on paracetamol
induced hepatotoxicity, suggests that the legislation has had a
specific effect. A decrease in overall suicide rates (including open
verdicts) occurred in England and Wales between 1998 and 2001
( − 11.8% for males and − 7.0% for females),19 but this was much
less than the results presented here.
Clearly the legislation does not prevent an individual intent
on obtaining large supplies from purchasing through multiple
outlets. Self poisoning is, however, often impulsive20 21 and
involves tablets readily available in households.11 Other countries
that have addressed this problem, such as France22 and Ireland,
have had greater reductions in pack sizes than the United King-
dom. Physiological investigations suggest that the risk of hepato-
toxicity after paracetamol overdose substantially increases with
consumption of 250 mg/kg or more tablets—that is, 30 tablets or
more for a person weighing 60 kg.23 A further small reduction in
pack sizes of paracetamol and salicylates would be unlikely to
inconvenience users and could have further beneficial effects in
preventing deaths from self poisoning.
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What is already known on this topic
Self poisoning with paracetamol and salicylates was a major
problem in the United Kingdom in the 1980s and 1990s
Outcomes included deaths, non-fatal self poisoning, and
liver transplantation due to paracetamol induced
hepatotoxicity
Legislation limiting the size of packs of analgesics seemed
to have a beneficial initial effect
What this study adds
Legislation limiting pack sizes of analgesics has had
sustained beneficial effects
Decreases have occurred in mortality, size of non-fatal
overdoses, and in admissions to liver units and liver
transplants due to paracetamol poisoning
Although some substitution with ibuprofen may have
occurred, there is no evidence that this has affected
mortality
Primary care
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